

Special Issue

Overcoming Chemoresistance in Cancer: Identifying Biomarkers and Novel Targets

Message from the Guest Editors

The development of chemoresistance remains the main obstacle in the successful treatment of cancer. There is no doubt that a great deal of work has been done in the last few years to increase our understanding of the mechanisms behind the development of drug resistance in cancer. However, the identification of new targets is crucial for the development of personalized therapeutic strategies aiming to overcome chemoresistance. In this Special Issue of *Cancers*, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: the identification of novel molecular mechanisms of chemoresistance; the discovery of novel molecular biomarkers to allow cancer patient stratification and personalized treatment; the discovery of new drug targets; and the development of novel combined treatments targeting multiple signaling pathways. We look forward to receiving your contributions.

Guest Editors

Dr. Annapina Russo

Dr. Giulia Russo

Dr. Annalisa Pecoraro

Deadline for manuscript submissions

closed (31 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/208814

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)